$6.350
-0.117 (-1.85%)收盘时
MSLE 盈利能力与利润率
Evaluating the bottom line, Satellos Bioscience Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.45%, provide a clear picture of how effectively MSLE converts its operational activities into shareholder value.
MSLE 同业对比
In the context of the broader market, MSLE competes directly with industry leaders such as PALI and PRQR. With a market capitalization of $134.75M, it holds a significant position in the sector. When comparing efficiency, MSLE's gross margin of N/A stands against PALI's 100.00% and PRQR's 100.00%. Such benchmarking helps identify whether Satellos Bioscience Inc. is trading at a premium or discount relative to its financial performance.
Satellos Bioscience Inc 财务表现
Satellos has reported significant net losses, with the latest quarterly net income at -9,768,000 USD and a negative EPS of -0.56. The company has a forward P/E of 0, indicating no earnings expected in the near term, and a current ratio of 11.22, showing good liquidity.
Financials
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。